Cargando…
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
BACKGROUND: CD19 chimeric antigen receptor T (CAR-T) cells demonstrate remarkable remission rates in pediatric and adult patients with refractory or relapsed (r/r) acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). In 2016, we initiated a clinical trial with in-house produced...
Autores principales: | Itzhaki, Orit, Jacoby, Elad, Nissani, Abraham, Levi, Michal, Nagler, Arnon, Kubi, Adva, Brezinger, Karin, Brayer, Hadar, Zeltzer, Li-at, Rozenbaum, Meir, Vernitsky, Helly, Markel, Gal, Toren, Amos, Avigdor, Abraham, Schachter, Jacob, Besser, Michal J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061891/ https://www.ncbi.nlm.nih.gov/pubmed/32152221 http://dx.doi.org/10.1136/jitc-2019-000148 |
Ejemplares similares
-
Impact of cryopreservation on CAR T production and clinical response
por: Brezinger-Dayan, Karin, et al.
Publicado: (2022) -
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
por: Nissani, Abraham, et al.
Publicado: (2021) -
Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies
por: Beider, Katia, et al.
Publicado: (2022) -
Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
por: Rozenbaum, Meir, et al.
Publicado: (2020) -
P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)